Centessa Pharmaceuticals plc entered into an underwriting agreement to issue and sell 10,810,810 American Depositary Shares (ADSs) at a price of $9.25 per ADS, with an option for the underwriters to purchase additional ADSs. The net proceeds from the offering, estimated to be approximately $93.5 million, will be used for the development of product candidates and general corporate purposes. The Company also announced its financial condition as of March 31, 2024, with cash, cash equivalents, and short-term investments of $230.2 million.